Calu-6 Xenograft Model Service for NSCLC

The Calu-6 xenograft model represents a robust, KRAS-mutant non-small cell lung cancer (NSCLC) platform widely utilized in preclinical oncology research for evaluating therapeutic efficacy, drug resistance mechanisms, and tumor biology. At Alfa Cytology, we provide comprehensive, GLP-compliant Calu-6 xenograft model services tailored to support your preclinical drug development pipeline—from initial tumor establishment and compound dosing to endpoint analysis and biomarker evaluation—ensuring reproducible, high-quality data to accelerate your research objectives.

Overview of Calu-6 Xenograft Model for NSCLC

The Calu-6 cell line was established in 1975 from the pleural effusion of a 61-year-old Caucasian female patient originally diagnosed with anaplastic lung carcinoma, now classified as poorly differentiated lung adenocarcinoma. Karyotypically hypotriploid with a modal chromosome number of 59 and 14 marker chromosomes, Calu-6 cells exhibit epithelial morphology and robust adherent growth properties. The cell line harbors a heterozygous KRAS p.Gln61Lys (Q61K) activating mutation and a homozygous TP53 p.Arg196Ter nonsense mutation, resulting in complete loss of p53 expression. These genetic alterations drive constitutive activation of the MAPK/ERK signaling cascade and abrogate DNA damage response pathways, conferring aggressive tumorigenic behavior, enhanced proliferation, and resistance to apoptosis. Calu-6 cells are tumorigenic in immunodeficient mice, forming poorly differentiated carcinomas that closely mimic the aggressive phenotype of KRAS-driven NSCLC in human patients. The model has been extensively validated across independent studies for its utility in evaluating chemotherapeutics, targeted agents, radiation sensitizers, and combination regimens, with documented responsiveness to DNA-damaging agents and anti-mitotic compounds.

In xenograft applications, Calu-6 tumors exhibit rapid, reproducible growth kinetics with palpable lesions typically appearing within 5–7 days post-implantation and reaching treatment volumes (100–200 mm³) within 10–14 days. The model is particularly valuable for investigating epithelial-to-mesenchymal transition (EMT), tumor stromal architecture, and angiogenic responses, as Calu-6 xenografts display a distinct tumor vessel phenotype characterized by reduced sensitivity to single-agent VEGFR tyrosine kinase inhibitors compared to stromal vessel-dominant models. Preclinical studies have demonstrated that Calu-6 tumors show dose-dependent growth inhibition with combination therapies (e.g., motesanib plus cisplatin or docetaxel), while exhibiting relative resistance to monotherapy anti-angiogenic agents, making this model an essential tool for studying therapeutic resistance and optimizing combination treatment strategies in KRAS-mutant NSCLC.

Fig 1. Combination of BGB-283 and selumetinib exhibited enhanced antitumor activity in human CRC and NSCLC xenograft models bearingK-RAS mutations. (Yuan, Xi, et al., 2020)

Cell Line Information: Calu-6

The Calu-6 cell line is a well-characterized human lung adenocarcinoma model with extensive documentation in peer-reviewed literature. The following table summarizes its key biological, genetic, and culture characteristics relevant to preclinical xenograft studies.

Our Services

Alfa Cytology delivers end-to-end Calu-6 xenograft model services designed to meet the rigorous demands of preclinical oncology research. Our experienced scientific team manages every phase of your study—from cell line authentication and quality control to tumor establishment, compound administration, and comprehensive endpoint analysis—ensuring reproducible, publication-ready data that supports your drug candidate's progression through the preclinical development pipeline. With flexible study designs, GLP-compliant workflows, and integrated biomarker capabilities, we provide the technical expertise and operational excellence you need to advance your NSCLC therapeutic programs with confidence.

Workflow of Calu-6 Xenograft Model Construction

The construction of a Calu-6 xenograft model follows a standardized, IACUC-approved protocol optimized for reproducible tumor growth and reliable therapeutic endpoint assessment. Each step is executed under strict quality control to ensure cell viability, sterility, and consistent tumor take rates.

1. Cell Culture and Expansion: Calu-6 cells are maintained in exponential growth phase under standard culture conditions (37°C, 5% CO₂) in RPMI 1640 or DMEM supplemented with 10% fetal bovine serum. Cells are passaged regularly to ensure log-phase status and mycoplasma-free certification prior to xenograft preparation.
2. Cell Authentication and Quality Control: Prior to injection, cells undergo STR profiling for identity verification and mycoplasma testing to confirm purity. Viability is assessed by trypan blue exclusion, with a stringent requirement of ≥98–99% viable cells to ensure robust tumor engraftment.
3. Cell Harvest and Preparation: Confluent Calu-6 cultures are gently trypsinized, washed, and resuspended in ice-cold phosphate-buffered saline (PBS) or a 1:1 mixture of PBS and Matrigel basement membrane matrix. The cell suspension is adjusted to a density of 1×10⁶ to 10×10⁶ cells per 100–150 µL injection volume.
4. Animal Preparation and Subcutaneous Injection: Female athymic nude mice (BALB/c nu/nu) or NOD/SCID mice, aged 6–12 weeks, are acclimatized under specific-pathogen-free (SPF) conditions. Each mouse receives a single subcutaneous injection of the Calu-6 cell suspension into the shaved right flank using a sterile 25-gauge needle.
5. Tumor Monitoring and Randomization: Injection sites are palpated three times weekly. Tumor dimensions are measured with digital calipers, and volumes are calculated using the modified ellipsoid formula (V = 0.5 × length × width²). Once tumors reach an average volume of 100–120 mm³, animals are randomized into treatment and control cohorts.
6. Compound Administration and Treatment: Test articles are administered according to the predefined dosing schedule via the specified route (oral gavage, intraperitoneal, intravenous, or subcutaneous). Vehicle controls receive matching placebo formulations. Body weights and clinical signs are monitored throughout the treatment period.
7. Longitudinal Tumor and Body Weight Assessment: Tumor volumes and animal body weights are recorded two to three times per week. Tumor growth inhibition (TGI) is calculated relative to vehicle-treated controls. Any animal showing >20% body weight loss or other significant clinical signs is evaluated for early humane endpoint criteria.
8. Study Termination and Necropsy: Animals are euthanized when tumors reach the predetermined size limit (typically ~2,000 mm³) or at the scheduled study endpoint. A complete necropsy is performed, including gross examination, tumor excision, weighing, and digital documentation.
9. Tissue Processing and Downstream Analysis: Excised tumors and tissues are processed according to study objectives: snap-frozen in liquid nitrogen for molecular analyses (Western blot, qPCR, RNA-seq), immersed in RNAlater for RNA stabilization, or fixed in 10% neutral buffered formalin for histopathology and immunohistochemistry.

Fig 2. Calu-6 xenograft model construction workflow.

Case Study-Calu-6 Xenograft Model Development

In a representative preclinical study utilizing the Calu-6 xenograft model, immunodeficient mice bearing established subcutaneous tumors were randomized to receive either vehicle control or a test compound targeting the VEGF signaling pathway, administered according to a predefined dosing regimen over a multi-week treatment period. Longitudinal monitoring demonstrated that the compound achieved dose-dependent tumor growth inhibition, with combination treatment arms showing enhanced efficacy compared to monotherapy. Endpoint analysis revealed significant reductions in final tumor weight, accompanied by decreased microvessel density on CD31 immunohistochemistry and downregulated phospho-VEGFR-2 expression by Western blot. Body weight profiles remained stable across all treatment groups, indicating acceptable tolerability. These findings illustrate the utility of the Calu-6 model for evaluating anti-angiogenic and combination therapeutic strategies in KRAS-mutant NSCLC, providing robust preclinical data to support downstream candidate selection and regulatory filing activities.

Why Choose Alfa Cytology?

Alfa Cytology combines deep scientific expertise with operational excellence to deliver Calu-6 xenograft model services that meet the highest standards of preclinical research. Our integrated platform is designed to accelerate your drug development timeline while ensuring data integrity and regulatory compliance.

• Extensive expertise in NSCLC xenograft models, with validated protocols for KRAS-mutant cell lines including Calu-6, ensuring high tumor take rates and reproducible growth kinetics.
• GLP-compliant and IACUC-approved vivarium operations, with all animal procedures conducted under strict ethical review and regulatory oversight.
• Comprehensive cell line authentication via STR profiling and mycoplasma screening, guaranteeing the genetic integrity and purity of every batch used in xenograft studies.
• Flexible, customizable study designs accommodating diverse therapeutic modalities—small molecules, biologics, ADCs, radiotherapy, and combination regimens—with multiple administration routes.
• Integrated biomarker and pharmacodynamic analysis capabilities, including immunohistochemistry, Western blotting, qPCR, flow cytometry, and histopathology, enabling mechanistic insights beyond standard efficacy endpoints.
• Rapid project turnaround with dedicated project management, providing real-time data access, detailed interim reports, and a comprehensive final study report formatted for regulatory submission or peer-reviewed publication.
• Competitive pricing and scalable capacity, from pilot feasibility studies to large-scale efficacy and toxicology evaluations, supporting programs from early discovery through late-stage preclinical development.

Contact Us

Ready to advance your NSCLC therapeutic program with a validated Calu-6 xenograft model? Contact us today to discuss your specific study requirements, receive a detailed project proposal, and learn how Alfa Cytology can support your preclinical research objectives with precision and reliability. Our scientific team is standing by to reach out and guide you through every step of your xenograft study—from initial consultation to final data delivery.

For research use only. Not intended for any clinical use.